- Home
- SLDB vs EVV Comparison
SLDB vs EVV Comparison
Compare SLDB & EVV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SLDB | EVV |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2017 | 2003 |
Fundamental Metrics
Financial Performance| Metric | SLDB | EVV |
|---|---|---|
| Price | $9.29 | $9.05 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $16.36 | N/A |
| AVG Volume (30 Days) | ★ 893.5K | 422.9K |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.97 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,094,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.79 | $8.97 |
| 52 Week High | $11.45 | $10.41 |
Technical Indicators
Market Signals| Indicator | SLDB | EVV |
|---|---|---|
| Relative Strength Index (RSI) | 56.37 | 34.99 |
| Support Level | $6.25 | $8.97 |
| Resistance Level | $11.45 | $9.32 |
| Average True Range (ATR) | 0.45 | 0.07 |
| MACD | 0.09 | -0.01 |
| Stochastic Oscillator | 66.77 | 12.70 |
Price Performance
Historical ComparisonAbout SLDB Solid Biosciences Inc.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
About EVV Eaton Vance Limited Duration Income Fund of Beneficial Interest
Eaton Vance Ltd Duration Income Fund is a diversified closed-end management investment company. The company's investment objective is to provide a high level of current income. The Fund also seeks capital appreciation. The Fund invests predominantly in Senior Floating-Rate Loans, Debt Obligations, Equity Securities, Derivatives as well as Foreign Securities and Currencies. The Fund invests in various industries, including aerospace and defense, automotive, building and development, healthcare, and leisure, among others.